SciTech Development, Inc.
281 Kercheval Avenue
Grosse Pointe Farms, MI 48236

Market Sector

- Pharmaceutical / Oncology

Products

- ST-001 nanoFenretinide is a multi-target cancer drug
- Novel delivery platform

Stage

- Clinical-stage
- Phase 1 clinical trials activated
- Clinicaltrials.gov: NCT04234048
- FDA approved second IND for small cell lung cancer. Trial may proceed.

Intellectual Property

- Patented:ST-001nanoFenretinide
- U.S. patent # 8709379B2
- E.U. patent # 2013016
- New patents filed - Q1 2025

Leadership Team

- CEO – Earle Holsapple
- CFO – Andrew Stumpf
- CSA – Ralph Parchment
- VPOps – Lou Scarmoutzos
- DStr – Michael Burns
- MDir – Ali Moiin
- IR/BD – David Schaffer

Investment

- Raised to Date: $15M+
- $20M Series A (Open now)

Use of Proceeds

- Continuation of Phase 1 trials for T-cell NHL
- Begin small cell lung cancer trials Q2 2025
- FDA filing submissions for commercialization
- Expand drug manufacturing
- Operating capital
- Scale management team

Investor Relations Contact

David R. Schaffer

DRS@SciTechDevelopment.com
+1 (727) 278-8188 (US)

SciTech Development, Inc

An oncology focused clinical-stage pharmaceutical company

ST-001 nanoFenretinide: Lead Drug Candidate in Clinical Trials

With innovative science and advanced nanotechnology, SciTech has developed ST-001 nanoFenretinide, a patented new drug with clinical trials in progress for T-cell lymphoma (a form of non-Hodgkin lymphoma). The FDA has approved a second IND in March 2025 that allows trial to proceed for the small cell lung cancer. FDA has granted ST-001 Orphan Drug Designation that allows for 7 years of market exclusivity once approved.

Clinical Trials Update

- Patient enrollment has completed for accelerated Phase 1a portion of trial for T-cell lymphomas
- Confirmed partial responses and stable disease observed
- Preliminary data supports that ST-001 is safe and tolerable at escalating dose levels and has shown efficient delivery of therapeutic doses
- Phase 1a standard stage of T-cell trial started dosing patients in Q1 2025
- Concurrent small cell lung cancer trial targeted to begin Q2 2025

Oncology Problem: Low Drug Bioavailability Severely Limited Clinical Use

Many cancer drugs have low bioavailability (absorption) due to water insolubility, resulting in sub-therapeutic dosing levels and insufficient amounts of drug being delivered to the cancer cells. Increasing dosage levels can lead to unacceptable toxicity levels and side effects. The active drug fenretinide presented low bioavailability challenges for use in cancer that remained unsolved - *Until now*.

Solution: ST-001 nanoFenretinide with Effective Drug Delivery Platform

ST-001 is a new, patented nanoparticle drug and delivery system that combines the active drug fenretinide with biocompatible phospholipids. ST-001 allows for the rapid intravenous (IV) infusion of high-dose fenretinide, ensuring safe and effective delivery to targeted tissue for therapeutic efficacy.

- Potential use in 15+ other cancer types based on previous studies
- Overcomes bioavailability challenges and triglyceride side effects seen with prior fenretinide formulations
- Delivers a 6-fold higher formulation strength than other prior formulations
- Studies show safety margin of 15x compared to previous IV formulations

Nanoparticle Drug Delivery Platform

- Delivery platform may be utilized with other related and/or similarly challenged hydrophobic drugs for new product pipelines.

SciTech Investment Highlights

- $20M Series A open now
- $15M+ total raised to date (2 oversubscribed funding rounds to date)
- Value inflection from encouraging trial data is now
- Funds will be used to advance:
  - Phase 1a/b trial in T-cell Lymphoma (~45 patients targeted)
  - Small cell lung trial (~44 patients targeted)
  - Drug manufacturing, patents, FDA filings for drug approvals, and operations

Corporate Strategy

- Receive FDA approval of ST-001 in T-cell lymphoma and small cell lung cancer
- Develop partnerships with pharmaceutical companies that want to expand their oncology pipeline and/or move into other targeted oncology domains
- ST-001 is positioned to help pharma overcome patent cliff and revenue losses
- Multiple exit options

Milestones and Achievements

- New Patents filed in Q1 2025
- Second IND approval for in small cell lung cancer: Trial to proceed
- T-cell trials in progress: Dosing patients with encouraging data
- Received ~$1M *gratis* supply of fenretinide from National Cancer Institute in 2024 to complete both T-NHL and SCLC clinical trials
- Completed ST-001 drug manufacturing for trial supply
- Added 6 key strategic advisors
- Orphan Drug Designation for cutaneous and peripheral T-cell lymphomas
- First IND received in 2019 from FDA for T-cell Lymphoma
- ST-001 patent granted in 2013 with US Patent extension to 2030
- Added 6 key strategic advisors

9 Activated Clinical Trial Sites

- City of Hope, Duarte, CA
- Columbia University Medical Center, New York City
- Hillman Cancer Center at University of Pittsburgh
- Karmanos Cancer Institute at Wayne State University, Michigan
- Keck School of Medicine at University of Southern California
- Mayo Clinic, Arizona
- MD Anderson Cancer Center at University of Texas
- Rogel Cancer Center at University of Michigan
- University of Colorado Cancer Center

Partners and Collaborators

- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- Karmanos Cancer Institute
  Wayne State University, MI
- Plough Manufacturing
  Memphis, TN
- BD/M Collective
  Henderson, NV

Law Firms

- Taft Law
- Wilson Sonsini Goodrich & Rosati

Bank

- First Citizens / SVB

For More Information:

- www.SciTechSDP.com
- SciTech@ScitechDevelopment.com

Fenretinide as a Therapeutic Agent

The drug fenretinide was initially developed by J&J and deemed safe in over 3,000+ patients in prior clinical trials. Due to bioavailability issues of past delivery vehicles, high drug concentrations could not reach and kill the cancer, resulting in non-FDA approval.

ST-001 combines fenretinide within SciTech's advanced delivery platform of specially formulated phospholipid bilayers that rapidly delivers effective doses of fenretinide to target tissue. Recent trial data shows fenretinide is actively being metabolized thereby overcoming bioavailability and toxicity challenges, and has shown partial responses and stable disease in T-cell lymphoma patients.

Multiple Mechanisms of Action

Fenretinide is a synthetic derivative of Vitamin A (a retinoid) that has been extensively studied for its potential anticancer properties. Several mechanisms of action have been identified for inducing cancer cell death such as; 1. Inhibiting the metabolism of retinoic acid, 2. Binding to retinoid receptors to damage mitochondrial function, 3. Modulation of cellular signaling pathways, 4. Inhibiting the formation of new blood vessels that can cause tumor growth and metastasis, 5. Activation of natural immune responses for potential immuno-therapeutic use.

A Large Target Market

US market opportunity for T-cell lymphoma, small cell lung cancer, and metastatic breast cancer is over $2B. ST-001 anticipated to be efficacious in lung, leukemia, head & neck, ovarian, cervical, and pancreatic cancers. Potential for use in 15+ additional cancers as stand-alone, complementary drug, or with chemotherapy agents. Significant revenue potential for new drug development with the delivery system which may increase the market potential to over $5B+.



An Experienced Leadership Team

Earle Holsapple, President & CEO; Director, Center for Cancer Economics, Technology Assessment, Innovation & Development (CETAID), Karmanos Cancer Institute; CEO/COO of six profitable, midsized corporations; Raised significant capital for 4 startups.

Ralph Parchment, Ph.D., Co-Founder and Chief Scientific Advisor; Pharmacologist, and Director of Multi-Laboratory Research Program, Frederick National Laboratory for Cancer Research. Discovered ST-001 and SDP Drug Delivery Platform while at Karmanos Cancer Institute.

Louis Scarmoutzos, Ph.D., VP Operations; Consultant to National Institute of Health (NIH) and the National Science Foundation commercialization programs, Drug development lead; Dual proficiency in science and business. Post-Doctoral Fellow in Chemistry/Chemical Biology at Harvard.

Ali Moiin, M.D., Medical Director; Board-certified dermatologist with extensive experience treating Cutaneous T-cell Lymphoma (CTCL) patients. Clinical Professor at Wayne State University, School of Medicine; Doctor of Medicine degree from University California, Davis.

Andrew Stumpf, MBA, Chief Financial Officer; Financial, accounting, and valuation advisory services to Fortune 500 and mid-market companies; Partner with Storm Lake Capital, VP for Stout Risius Ross Advisors, and auditor with Ernst & Young.

Michael Burns, Ph.D., MBA, Director, Corporate and Strategic Development; Former President and COO of Ferndale Pharmaceutical Group; Extensive pharmaceutical industry experience including product development, R&D, sales and marketing, licensing, and M&A.

David R. Schaffer, Director, Investor Relations and Business Development; Experience in global equity markets, investment banking, investor relations, and strategic advisory to public/private funds, most notably as Managing Director with Raymond James and previously with Advest.

Bill Werkmeister, MBA, Director, Venture Investments; HRN Family Office, Advisory Board of National Foundation for Cancer Research, Founder of MedInvest Conference.

John Chapman, CPA, Advisor; Sr. Partner and Global Chair of KPMG's Pharmaceutical Practice (Ret.) and recognized financial industry expert by the Securities and Exchange Commission (SEC).

Ken Massey, Ph.D., Advisor; Sr. Director of Venture Development at Karmanos Cancer/Wayne State, Assistant professor at the University of Michigan Medical School, and managing director of LifeLine Ventures.

Exceptional Medical Advisory Board

Larisa Geskin, M.D.; Director, Comprehensive Cutaneous Oncology Center at Columbia University.

Ajay Gopal, M.D.; Medical Director, Clinical Research and Hematology at Fred Hutchinson Cancer Center.